Colorectal carcinoma (CRC) · line 1 · FOLFOX (mFOLFOX6)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-FOLFOX |
| ID | IND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOX |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-03 | pending_clinical_signoff |
| Diseases | DIS-CRC |
| Sources | SRC-ESMO-COLON-2024 SRC-MOSAIC-ANDRE-2004 SRC-NCCN-COLON-2025 |
Notes
High-risk stage II colon cancer only. MSI/MMR testing is the single most important pre-decision test. Low-risk stage II (T3 N0, ≥12 nodes, no adverse features, MSS) — observation preferred; adjuvant chemotherapy does not improve outcomes.
Used By
Algorithms
ALGO-CRC-ADJUVANT- ALGO-CRC-ADJUVANT